Individuals or couples of reproductive age can have testing through Genome Shield for mutations in a panel of recessive genes which are associated with a group of serious and rare disorders that primarily develop in infancy and childhood. The purpose of recessive gene carrier screening is to identify couples who are at high risk for having a child with a disorder included in the testing panel. Being forewarned about the high risk of a child with a serious medical problem can help in planning for future pregnancies, arranging for diagnostic testing during an ongoing pregnancy, and in preparing for the birth of a child who might have special needs
Genome Shield offers testing for a multiple panel of mutations in 20 breast and ovarian susceptibility genes including BRCA1 and BRCA2. The test will be offered to women who have been diagnosed with breast and/or ovarian cancer, or who are at high risk for these malignancies based on family history. Testing will be ordered by medical oncologists or genetic specialists. Identification of cancer susceptibility gene mutations has implications for disease prevention, surveillance, early detection, therapy, and assessment of risk in other family members.
Clinical Data Collection and Biomarker Discovery.
Our Commercial model naturally ties into Research and Development. The clinical data we collect will be used for the discovery of biomarkers, which will be cycled back into product development. We will pursue research and development in house and in collaboration with leading Institutions across the globe.